

( (S (NP-SBJ (NP Sandoz AG)
             ,
             (NP a major Swiss (ADJP chemical and pharmaceutical) group)
             ,)
     (VP said
         (SBAR that
               (S (NP-SBJ its group sales)
                  (VP rose
                      (NP-EXT 25 %)
                      (PP-DIR to
			      (NP (NP (QP 9.482 billion) francs)
				  (PRN -LRB-
				       (NP (QP $ 5.80 billion) *U*)
				       -RRB-)))
		      (PP-TMP in
			      (NP (NP the first nine months)
				  (PP of
				      (NP this year))))
		      ,
		      (PP with
			  (NP (NP strong gains)
			      (PP-LOC in
				      (NP all divisions))))))))
     .))
( (S (ADVP-TMP (NP A year)
	       earlier)
     (NP-SBJ sales)
     (VP totaled
         (NP (QP 7.567 billion) francs))
     .))
( (S (NP-SBJ (NP Positive currency rates)
             and
             (NP strong sales growth))
     (VP led
         (PP-CLR to
		 (NP (NP a substantial rise)
		     (PP-LOC in
			     (NP consolidated profit))))
	 (PP-TMP in
		 (NP the period))
	 ,
	 (SBAR-ADV although
		   (S (NP-SBJ the company)
		      (VP did n't
			  (VP provide
			      (NP figures)
			      ,
			      (SBAR  (WHNP-1 0) 
				     as
				     (S (NP-SBJ *T*-1)
					(VP is
					    (ADJP-PRD customary)
					    (PP with
						(NP Swiss companies))))))))))
     .))
( (S (NP-SBJ Sandoz)
     (VP said
         (SBAR 0
               (S (NP-SBJ it)
                  (VP expects
                      (NP (NP a `` substantial increase '')
                          (PP-LOC in
				  (NP consolidated profit))
                          (PP-TMP for
				  (NP the full year)))
		      ,
		      (S-SBJ (NP-SBJ *)
			     (VP barring
				 (NP major currency rate changes)))))))
     .))
